FIELD: pharmacology.
SUBSTANCE: essence is that a pharmaceutical composition has been created for a prolonged release of an anti-inflammatory peptide Ingramon or its salt, where the specified peptide is represented by the following sequence: H-Asp-His-Leu-Asp-Lys-Gln-Thr-Gln-Thr-Pro-Lys-Thr-OH, wherein the composition further comprises a pharmaceutically acceptable biodegradable polymer.
EFFECT: invention provides a prolonged release of the active substance.
4 cl, 16 ex, 1 tbl, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE FOR INHIBITING FRACTALKINE-STIMULATED MIGRATION OF MONOCYTIC CELLS | 2011 |
|
RU2461565C1 |
| PEPTIDE ELICITING CAPACITY TO INHIBIT MIGRATION OF MONOCYTIC CELLS STIMULATED BY PROTEIN MCP-1 | 2003 |
|
RU2260598C2 |
| METHOD FOR EVALUATING SEVERITY OF TISSUE ISCHEMIA OF LOWER EXTREMITIES IN PATIENTS WITH OBLITERATING ARTERIAL SCLEROSIS OF LOWER EXTREMITIES | 2012 |
|
RU2473082C1 |
| USE OF MCP-1 FOR INDUCTION OF READINESS OF UTERUS CERVIX TO OPENING | 1995 |
|
RU2207873C2 |
| ANTIBODIES AGAINST EOTAXIN 2, WHICH RECOGNIZE ADDITIONAL CCR3-BINDING CHEMOKINES | 2015 |
|
RU2705255C2 |
| ANTIBODIES FIGHTING MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) AND THEIR APPLICATION | 2003 |
|
RU2339647C2 |
| RIFAMPICIN-BASED MEDICATION WITH PROLONGED ACTION FOR TREATMENT OF RESISTENT FORMS OF TUBERCULOSIS | 2010 |
|
RU2418585C1 |
| USE OF PEPTIDE FOR TREATMENT OF CARDIOVASCULAR DISEASES | 2013 |
|
RU2672341C2 |
| CELL-BASED THERAPY OF ISCHEMIC TISSUE | 2009 |
|
RU2535966C2 |
| SYNTHETIC ANALOGS OF IL-10 | 1997 |
|
RU2194054C2 |
